Immune responses against pathogens require that microbial components promote the activation of antigen-presenting cells (APCs). Autoimmune diseases and graft rejections occur in the absence of pathogens; in these conditions, endogenous molecules, the so-called 'innate adjuvants', activate APCs. Necrotic cells contain and release innate adjuvants; necrotic cells also release high-mobility group B1 protein (HMGB1), an abundant and conserved constituent of vertebrate nuclei. Here, we show that necrotic HMGB1 À/À cells have a reduced ability to activate APCs, and HMGB1 blockade reduces the activation induced by necrotic wild-type cell supernatants. In vivo, HMGB1 enhances the primary antibody responses to soluble antigens and transforms poorly immunogenic apoptotic lymphoma cells into efficient vaccines.
INTRODUCTION
Signals produced by microbes favour the establishment of adaptive immune responses. The presence of microbial structures reveals an infection, and their recognition is achieved by receptors on cells of the innate immune system, in particular Toll-like receptors (TLRs). The activation of TLRs on antigen-presenting cells (APCs) triggers a coordinated series of events, including the upregulation of molecules involved in antigen presentation and Tcell costimulation, known as 'maturation'.
The maturation of APCs is also necessary for immune responses that occur in the absence of pathogens (Steinman & Nussenzweig, 2002) . However, the adjuvant signals involved are less characterized. Tissue damage per se activates immune responses (Kurts et al, 1998; Srivastava et al, 1998; Gallucci et al, 1999; Savill et al, 2002) . Injured tissue evokes acute but generally transient immune responses against 'self' constituents (Savill et al, 2002; Bondanza et al, 2003) . Antigens from dying cells are preferentially recognized in vivo (Kurts et al, 1998) , and dying cells release adjuvant factors that amplify and sustain T-cell-dependent immune responses, in situ and at a distance (Shi & Rock, 2002) . Recently, uric acid has been identified as an endogenous immune adjuvant (Shi et al, 2003) , but it is not likely to be the only one.
The high-mobility group B1 protein (HMGB1) is a nuclear constituent loosely bound to chromatin, and a mediator of inflammation in the extracellular environment (Wang et al, 1999 (Wang et al, , 2004 . Damaged and necrotic cells release HMGB1 (Scaffidi et al, 2002) ; in contrast, the chromatin of apoptotic cells sequesters HMGB1. Extracellular HMGB1 is responsible for the inflammatory response to cell necrosis, as shown in a model of acute liver toxicity (Scaffidi et al, 2002) . RAGE (receptor for advanced glycation end products) is a surface receptor for HMGB1 (Huttunen & Rauvala, 2004) , but others may exist (Park et al, 2004) . RAGE activation results in nuclear factor-kB (NF-kB) translocation (Andersson et al, 2002) , and the NF-kB pathway is responsible for most events elicited by necrotic cells (Li et al, 2001) .
In this study, we have identified HMGB1 as an innate adjuvant that favours immune responses in vivo against soluble and cellassociated antigens.
RESULTS AND DISCUSSION
T-cell priming and initiation of adaptive immune responses require the maturation of the most potent APCs, the dendritic cells (DCs). As expected (Gallucci et al, 1999; Sauter et al, 2000) , human monocyte-derived DCs matured when challenged with necrotic HeLa cells (Fig 1A) . Cell constituents released into the supernatant were sufficient to cause DC maturation (Fig 1A) . In contrast, DCs challenged with low numbers of early apoptotic cells or their supernatant did not mature (Rovere et al, 1998; Gallucci et al, 1999; Sauter et al, 2000) (data not shown).
We verified whether HMGB1 in necrotic cell supernatants was required to trigger maturation. The addition of HMGB1-specific antibodies or of the HMGB1 inhibitory fragment box A (Palumbo et al, 2004) to the supernatants of necrotic HeLa cells abrogated DC maturation (Fig 1C) . Fibroblasts from wild-type or Hmgb1 À/À mice ( Fig 2A) were necrotized; supernatants from wild-type cells contained HMGB1, whereas those from Hmgb1 À/À cells did not (Fig 2B) . Only supernatants containing HMGB1 activated the DCs, as shown by the upregulation of membrane markers (HLA-DR, CD40, CD83, CD80 and CD86) and the induction of TNF-a secretion; the insoluble fraction from wild-type or À/À necrotic cells was not active (Fig 2C-E) . The addition of recombinant HMGB1 to the supernatant of necrotic À/À fibroblasts only partly reconstituted the effect of the endogenous counterpart, suggesting a possible role for intracellular regulatory activities (Fig 2E) . Necrotic wild-type cell supernatants complemented with anti-HMGB1 antibodies and necrotic À/À cell supernatants had similar effects on the DC activation state.
In living polymorphonuclear neutrophils (PMNs), HMGB1 is contained in cytoplasmic vesicles as well as in the nucleus ( Fig  1B) . Necrotic PMNs do not release HMGB1 ( Fig 1D) ; the protein is tightly associated with an insoluble fraction and fails to be released by treatment with ionic and nonionic detergents. Necrotic PMN supernatants, which therefore do not contain HMGB1, did not trigger DC maturation (Fig 1A) .
We then tested whether HMGB1 was involved in the adjuvant activity of necrotic cells in vivo. We injected C57BL/6 mice with apoptotic RMA lymphoma. After 14 days, we challenged them with a large number of living lymphoma cells and evaluated the development of lymphoma (Fig 2E,F) . Apoptotic lymphoma cells syngeneic to C57BL/6 mice are poorly immunogenic (Ronchetti et al, 1999) : all mice subsequently challenged with living lymphoma cells developed the tumour within 10 days. We then injected C57BL/6 mice with apoptotic lymphoma cells together with the supernatants of necrotic fibroblasts, either wild type or Hmgb1 À/À . The mice that had received wild-type necrotic cell supernatants rejected the tumour; 80 days later, they also rejected a further challenge with living lymphoma cells, indicating that the response was long-lasting. Supernatants of necrotic Hmgb1 À/À fibroblasts were less efficient in eliciting a protective immune response: 75% of the mice developed lymphomas and eventually died. The blockade of HMGB1 with antibodies reduced (but did not abolish completely) the protection elicited by necrotic À/À cell supernatants by 50%. HMGB1 is an immune adjuvant P. Rovere-Querini et al HMGB1 is an immune adjuvant P. Rovere-Querini et al These results indicate that HMGB1 released by necrotic cells is a potent adjuvant in vivo and that other intracellular components contribute to the adjuvant activity of necrotic cell supernatants. Candidates include heat-shock proteins (Basu et al, 2000) and uric acid (Shi et al, 2003) ; significantly, uric acid can derive from the breakdown of adenosine triphosphate (ATP)-itself a cell component released by necrotic cells-by phosphodiesterases and other enzymes, such as xanthine oxidase that can be found in extracellular fluids (Hare & Johnson, 2003) .
We then verified whether purified recombinant HMGB1 obtained from prokaryotic or eukaryotic cells (Fig 3) was comparable in its adjuvant activity with the natural protein released by necrotic cells. We first verified whether recombinant HMGB1 influenced the primary antibody response against exogenous soluble antigens, a well-characterized feature of endogenous adjuvants (Le Bon et al, 2001 ). We immunized mice by injecting ovalbumin (OVA) subcutaneously, either in the presence or absence of HMGB1; control mice were injected with phosphate-buffered saline (PBS) or HMGB1 alone. Coinjection with HMGB1 elicited a striking increase in OVA-specific IgG antibody titres (Fig 4A; Po0.001). Similar effects on OVA immunogenicity were obtained in wild-type C57BL/6 mice, wild-type lipopolysaccharide (LPS)-responsive C3H/HeN mice and in C3H/HeJ mice, which are LPS-resistant due to a mutation in TLR4 (Fig 4A,B) . This result indicates that contamination with bacterial endotoxin is not involved. Recombinant HMGB1 obtained from prokaryotic or eukaryotic cells exerted similar effects in vivo (compare HMGB1 with His-HMGB1 in Fig 4B) . HMGB1 per se did not induce the production of OVA-specific IgG antibodies (Fig 4A,B) . At the concentration we used, HMGB1 was consistently less potent than complete Freund's adjuvant, an oilin-water emulsion containing heat-killed Mycobacterium tuberculosis, considered the gold standard against which all adjuvants are measured.
We then verified whether HMGB1 behaved as an adjuvant for cell-associated antigens by injecting apoptotic RMA lymphoma cells in the presence or absence of recombinant HMGB1. Apoptotic lymphoma cells alone were poorly immunogenic: all mice injected with apoptotic lymphoma cells alone developed the tumour (Fig 4C) . In contrast, 80% of mice injected with RMA apoptotic cells and HMGB1 rejected the later challenge with living RMA lymphoma cells (Fig 4C) . The response was longlasting, because surviving mice rejected an additional lethal challenge with living lymphoma cells 80 days later (Fig 4C) .
Our data suggest that the HMGB1 acts as a bona fide endogenous adjuvant. This is consistent with the general message conveyed by extracellular HMGB1-namely, that tissue damage has occurred (Bianchi & Manfredi, 2004) . It also makes good sense from an evolutionary point of view: it is advantageous to activate the immune system immediately after trauma, because infection may follow shortly. HMGB1 is also actively secreted by monocytes and macrophages on activation by LPS, tumour necrosis factor-a (TNF-a) or interleukin-1b (IL-1b) (Wang et al, 1999; Andersson et al, 2000) . In myeloid cells, HMGB1 is secreted through specific organelles, the secretory lysosomes (Gardella et al, 2002) , and is extensively acetylated in order to reach them from the nucleus (Bonaldi et al, 2003) . Thus, HMGB1 secreted actively by inflammatory cells is molecularly different from HMGB1 released passively by necrotic cells. We have no reason to believe that the secreted protein cannot activate immune responses, but this should be verified formally when adequate amounts of acetylated HMGB1 become available.
Whereas the blockade of extracellular HMGB1 might represent a suitable therapeutic target for the treatment of sepsis (Wang et al, 2004) and rheumatoid arthritis (Andersson & Erlandsson-Harris, 2004) , the local administration of recombinant HMGB1 may enhance the immune responses against cancer.
METHODS
Cells. DCs and PMNs were derived from the blood of healthy donors (Rovere et al, 2000) . Embryonic fibroblasts from H-2 b C57BL/6 wild-type and Hmgb1 À/À mice (Calogero et al, 1999) and H-2 b RMA lymphoma cells were grown in RPMI 1640 (Life Technologies, Grand Island, NY, USA) containing 10% FCS (HyClone, Logan, UT, USA). Cells were tested for mycoplasma by PCR. Immature DCs were challenged with necrotic or apoptotic cells (dead cells:DCs ratio ¼ 1:2), or their supernatants and insoluble fraction. When indicated, experiments were performed with or without anti-HMGB1 polyclonal antibodies (BD Biosciences PharMingen, San Diego, CA, USA), irrelevant rabbit polyclonal antibodies or the inhibitory HMGB1 fragment box A (Palumbo et al, 2004) . Maturation was assessed after 48 h (Rovere et al, 1998) . Apoptosis and necrosis. Cells were killed by necrosis after three cycles of freezing and thawing (Sauter et al, 2000) . Apoptosis was induced by ultraviolet irradiation and verified as described (Bellone et al, 1997; Ronchetti et al, 1999) . HMGB1 is an immune adjuvant P. Rovere-Querini et al HMGB1 production and detection. Mouse and human HMGB1 sequences have only two conservative substitutions. Full-length HMGB1 and the inhibitory HMGB1 box A fragment were expressed and purified as described (Palumbo et al, 2004) . Endotoxins were removed by passage over Detoxy-Gel (Pierce Biotechnology Inc., Rockford, IL, USA). Indirect immunofluorescence was performed using anti-HMGB1 polyclonal antibodies (BD Biosciences, PharMingen) and fluorescein isothiocyanate (FITC)-conjugated anti-rabbit antibodies (Boehringer); nuclei were counterstained with 4 0 -6 diamidino-2-phenylindole (DAPI, SigmaAldrich, St Louis, MO, USA; Scaffidi et al, 2002) . For expression in eukaryotic cells, full-length HMGB1 was cloned into the pcDNA 4/HisMax vector (Invitrogen), which allowed for the insertion of a poly-histidine (6 Â His) tag at the amino-terminus (His-HMGB1). His-HMGB1 was transiently expressed in COS7 cells after transfection with diethylaminoethyl-dextran. After 48 h, cells were lysed and His-HMGB1 purified in a Ni 2 þ -chelating Sepharose column (Amersham) and ultrafiltred on polyethersulphone membranes (Vivascience). Immunoblots were performed using anti-His (Clontech Laboratories Inc.) or anti-HMGB1 antibodies and horse radish peroxidase (HRP)-conjugated antimouse or anti-rabbit second-step reagents (Amersham). Purity was evaluated by Coomassie staining of sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE).
Immunization. C57BL/6 mice were injected subcutaneously (s.c.) twice every other week with PBS or 10 6 apoptotic RMA cells, in the presence or the absence of HMGB1 (0.5 mg/mouse), or supernatants from necrotic wild-type or Hmgb1 À/À fibroblasts. Supernatants of 5 Â 10 6 wild-type fibroblasts contained approximately 500 ng of HMGB1. In selected experiments, the effect of anti-HMGB1 antibodies on the supernatants of wild-type and À/À fibroblasts was evaluated. Endotoxin contamination was assessed by the kinetic-QLC Limulus test (BioWhittaker, Walkersville, MD, USA) and was under the limits of detection (lower than 0.03 U/ mouse). After 14 days, mice were challenged s.c. in the opposite flank with 50 Â 10 3 living RMA cells, and tumour appearance and size were evaluated (Ronchetti et al, 1999) . Protected mice were rechallenged with living RMA cells after 80 days. C57BL/6 mice, wild-type LPS-responsive C3H/HeN mice and C3H/HeJ mice, which are LPS resistant due to a mutation in TLR4 (Jackson Laboratory), were immunized with purified OVA (10 mg/mouse, Sigma-Aldrich) alone, OVA in CFA (Pierce, Rockford, IL, USA) or with OVA in the presence or the absence of HMGB1 or His-HMGB1 (1 mg/mouse). OVA-specific antibodies were assessed by ELISA: 96-well plates (Nunc) were coated with OVA (10 mg/ml) and blocked with FCS; diluted sera were added and samples developed by sequential incubation with HRP-conjugated b HMGB1 is an immune adjuvant P. Rovere-Querini et al IgG-specific monoclonal antibody and substrate (Sigma). Results are expressed as end-point titres, which were the highest serum dilutions that gave an optical density reading five times above that of control samples. The background level was very low at all dilutions and did not vary significantly between experiments.
